Abstract:e14521 Background: Human leukocyte antigen (HLA) molecules are essential components involved in tumor antigen presentation. Loss of heterozygosity in HLA (HLA LOH) may facilitate tumor immune evasion. However, the large population study of HLALOH in Chinese pan-cancer patients remains to be explored. Methods: In this study, analysis were performed in 1504 advanced patients across 12 cancer types and 134 early-stage NSCLC patientsusing a 1021-gene panel. HLA LOH were analysis using LOHHLA algorithm. The consistency between target sequencing by 1021-gene panel and whole-exome sequencing (WES) was evaluated in 45 samples. Results: In 45 samples processed with both approaches, 95.6% (43/45) obtained concordant results. Among the 1638 patients, 24 were excluded due to homozygosity at all three HLA-Iloci. The prevalence of HLALOH in advanced patients presented considerable differences among cancer typeswith an average incidence of 45.6% (676/1482), ranging from 12.2% (prostate adenocarcinoma) to 68.0% (cervical squamous cell carcinoma). In NSCLC patients, there was an enrichment of HLALOH in both early-stage (I-IIIa) LUSC (24/88 [27.3%] of LUAD vs. 26/42 [61.9%] of LUSC, p<0.001) and advanced (IIIb-IV) LUSC. In 43.3% (293/676) patients harboring HLALOH, LOH co-occurred in HLA-A, B, and C. Consistent with previous studies, the occurrence of HLALOH was relevant to an elevated TMB level(median TMB 6.72 vs. 5.76, p<0.0001). In addition, the TMB level of patients with LOH at all three HLA-I loci was higher than those with LOH at only one HLA-I locus (median TMB 7.68 vs. 6.72, p=0.027).However, despite that MSI-H patients presented the highest incidence of TMB-H (TMB≥10.56), the incidence of HLALOH decreased in these patients. Alterations of multiple signaling pathways are enriched in HLALOH patients, including CPF (checkpoint factor) pathway, FA (Fanconi anemia) pathway, p53 pathway, RTK/RAS pathway, Notch pathway, Hippo pathway and Nrf2 pathway(p<0.0001, p=0.023, p<0.0001, p<0.0001, p=0.032, p=0.013, p=0.003, respectively, Table).Several oncogenes, such as TP53 and LRP1B, had higher alteration frequencies in the HLALOH group(p<0.001 for TP53,p<0.05 for LRP1B, Table 1). Conclusions: The 1021-gene panel could be applied for HLALOH analysis, provided that the relevant regions are well captured. The prevalence of HLALOH in Chinese cancer patients presents considerable differences across cancer types. Besides, the occurrence of HLA LOH was accompanied by higher alteration frequencies in several oncogenes and oncogenic signaling pathways. These insights may provide valuable information for clinical practice and follow-up research.[Table: see text]

Detection and significance of loss of heterozygosity of the tumor suppressor gene Tg737 in the side population cells of hepatocellular carcinomas

Mutation Analysis of Novel Human Liver-Related Putative Tumor Suppressor Gene in Hepatocellular Carcinoma

The Association of Frequent Allelic Loss on 17p13.1 with Early Metastastic Recurrence of Hepatocellular Carcinoma after Liver Transplantation

[Loss of heterozygosity of plasma circulating DNA from hepatocellular carcinoma patients and its clinical significance].

The prognostic value of chromosomal loss of heterozygosity in molecular staging for TNM stage Ⅰ of hepatocellular carcinoma

The Roles of Loss of Heterozygosity at 8p22 in the Molecular Classification of Patients with Hepatocellular Carcinoma, with Special Reference to Survival after Surgical Operation

Relation of HCC to Loss of Heterozygosity

Loss of Heterozygosity on Chromosome 10Q22-10Q23 and 22q 11.2- 22q 12.1 and P53 Gene in Primary Hepatocellular Carcinoma

Loss of Heterozygosity at D8S298 is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Loss of Heterozygosity Analysis on Chromosome 8p in Hepatocellular Carcinoma Based on Laser Capture Microdissection

Microsatellite alterations of circulating DNA in the plasma of patients with hepatocellular carcinoma

Identification of Prognostic miRNAs Targeting EZH2 in Hepatocellular Carcinoma Using The Cancer Genome Atlas Database

Identification of the Clonal Disparity among Different Tumor Cell Groups in the Same Hepatocellular Carcioma Nodule by Using Loss of Heterozygosity of Chromosome 8p Microsatellite

The value of chromosomal loss of heterozygosity in prognosis prediction of hepatocellular carcinoma patients with curative resection

[Refined Mapping of Loss of Heterzygosity on 10Q23-24 in Sporadic Colorectal Carcinoma].

[Loss of Heterozygosity Analysis to Define Putative Region Involved in Tumor Differentiation and Metastases in Sporadic Colorectal Cancer Patients].

Identification of Side Population Cells in Human Hepatocellular Carcinoma Cell Lines with Stepwise Metastatic Potentials

Loss of Heterozygosity at D14S62 and D14S51 Detected by a Simple and Non-Radioactive Method in Plasma DNA is a Potential Marker of Metastasis and Recurrence after Curative Hepatic Resection in Hepatocellular Carcinoma.

The prevalence of HLA LOH in Chinese pan-cancer patients and its correlation with genomic alterations.

[Single receptor system in the compound eye of crabs (Scylla serrata)].